PUBLISHER: The Business Research Company | PRODUCT CODE: 2036138
PUBLISHER: The Business Research Company | PRODUCT CODE: 2036138
Tumor exosome profiling involves the analysis and characterization of exosomes, which are small extracellular vesicles released by tumor cells containing molecular information such as proteins, RNA, and DNA. This profiling provides insights into tumor biology, helps identify biomarkers, and supports the development of diagnostic or therapeutic strategies for cancer management.
The key product types of tumor exosome profiling include kits and reagents, instruments, software, and services. Kits and reagents isolate, detect, and analyze exosomes from biological samples, enabling accurate disease diagnostics and research. Sample types include blood, urine, saliva, and others. Applications include cancer diagnostics, prognostics, therapeutics, and research, serving hospitals, clinics, research institutes, diagnostic laboratories, and other end users.
Tariffs have influenced the tumor exosome profiling market by raising the cost of importing specialized instruments, kits, and reagents required for profiling. This has primarily impacted segments such as instruments and kits, especially in regions like North America and Europe that rely heavily on imports for advanced laboratory equipment. However, tariffs are encouraging local manufacturing and innovation, driving the development of cost-efficient, domestically produced solutions and fostering market resilience.
The tumor exosome profiling market research report is one of a series of new reports from The Business Research Company that provides tumor exosome profiling market statistics, including tumor exosome profiling industry global market size, regional shares, competitors with a tumor exosome profiling market share, detailed tumor exosome profiling market segments, market trends and opportunities, and any further data you may need to thrive in the tumor exosome profiling industry. This tumor exosome profiling market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The tumor exosome profiling market size has grown rapidly in recent years. It will grow from $1.13 billion in 2025 to $1.32 billion in 2026 at a compound annual growth rate (CAGR) of 16.9%. The growth in the historic period can be attributed to growing cancer prevalence, advances in molecular biology techniques, increasing adoption of liquid biopsy methods, rising research funding for oncology, demand for non-invasive diagnostic tools.
The tumor exosome profiling market size is expected to see rapid growth in the next few years. It will grow to $2.49 billion in 2030 at a compound annual growth rate (CAGR) of 17.1%. The growth in the forecast period can be attributed to integration of ai and bioinformatics in exosome profiling, development of personalized medicine solutions, expansion of diagnostic laboratories, adoption of high-throughput exosome analysis platforms, growth in cancer biomarker discovery. Major trends in the forecast period include liquid biopsy integration, high-throughput exosome analysis, automated sample preparation, multi-omics data profiling, personalized cancer therapeutics.
The increasing prevalence of cancer is anticipated to drive the growth of the tumor exosome profiling market in the coming years. Cancer encompasses a group of diseases characterized by uncontrolled proliferation and division of abnormal cells, which can invade nearby tissues and metastasize to other body regions. The rise in cancer prevalence is attributed to unhealthy lifestyles, including poor nutrition, physical inactivity, smoking, and excessive alcohol consumption, all of which elevate the risk of various cancer types. Tumor exosome profiling aids cancer management by enabling early detection, monitoring tumor progression, and guiding personalized therapy through analysis of tumor-derived exosomes in body fluids. For instance, in February 2024, according to the World Health Organization, a Switzerland-based international organization specializing in global health policy and public health initiatives, over 35 million new cancer cases are projected in 2050, representing a 77% increase from the estimated 20 million cases in 2022. Therefore, the increasing prevalence of cancer is propelling rapid growth in the tumor exosome profiling market.
Key companies operating in the tumor exosome profiling market are focusing on developing innovative solutions, such as liquid biopsy-based exosome assays, to enable early cancer detection and personalized therapy monitoring. A liquid biopsy-based exosome assay is a blood test that detects tiny vesicles called exosomes released by tumor cells, allowing doctors to identify and monitor cancer without invasive tissue biopsies. For example, in June 2024, Mercy BioAnalytics Inc., a US-based biotechnology company, partnered with University College London (UCL), a UK-based university, to launch the Mercy Halo Ovarian Cancer Screening Test, a next-generation extracellular vesicle liquid biopsy designed to identify ovarian cancer in asymptomatic, postmenopausal women by detecting multiple co-localized cancer biomarkers on individual tumor-derived vesicles using a low-volume blood sample and quantitative polymerase chain reaction (qPCR)-based readout, offering high sensitivity and specificity several years before clinical diagnosis.
In September 2025, MDxHealth SA, a Belgium-based healthcare technology company, acquired Exosome Diagnostics, Inc. from Bio Techne Corporation for $15 million. With this acquisition, MDxHealth seeks to expand its liquid-based diagnostic offerings and reinforce its leadership in prostate cancer diagnostics by integrating ExoDx prostate cancer testing and associated clinical laboratory assets. Exosome Diagnostics Inc. is a US-based healthcare technology company that specializes in comprehensive, proprietary tumor exosome profiling and liquid biopsy services.
Major companies operating in the tumor exosome profiling market are Thermo Fisher Scientific Inc., Lonza Group Ltd., NanoFCM Inc., QIAGEN N.V., Bio-Techne Corporation, Miltenyi Biotec B.V. And Co. KG, Aethlon Medical Inc., Cusabio Technology LLC, Norgen Biotek Corp., Kimera Labs Inc, Diagenode Inc., Creative Biolabs Inc, Izon Science Ltd., System Biosciences LLC, Mercy Bioanalytics Inc, MtoZ Biolab, Capital Biosciences Inc., ExoCan Healthcare Technologies Private Limited, INOVIQ Ltd, Codiak BioSciences Inc.
North America was the largest region in the tumor exosome profiling market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tumor exosome profiling market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the tumor exosome profiling market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The tumor exosome profiling market consists of revenues earned by entities by providing services such as exosome isolation and purification, next-generation sequencing (ngs) services, custom exosome research services, exosome biomarker discovery and validation, and exosome-based liquid biopsy services. The market value includes the value of related goods sold by the service provider or included within the service offering. The tumor exosome profiling market also includes sales of exosome analysis and characterization instruments, bioinformatics software and analytics tools, affinity based isolation columns and spin column kits, high throughput microfluidic platforms, and exosome biomarker profiling libraries and reagents. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Tumor Exosome Profiling Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses tumor exosome profiling market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for tumor exosome profiling ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The tumor exosome profiling market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.